Piezo1 agonist 1-d2
Piezo1 agonist 1-d2 is a Piezo1 agonist and osteogenesis promoter with an EC50 of 2.21 μM. Piezo1 agonist 1-d2 activates Piezo1 and induces calcium ion influx in mesenchymal stem cells. Piezo1 agonist 1-d2 activates the Erk signaling pathway and promotes osteogenesis of mesenchymal stem cells. Piezo1 agonist 1-d2 alleviates disuse osteoporosis in a hindlimb unloading rat model. Piezo1 agonist 1-d2 can be used for research on osteoporosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3058199-62-2
- Formule: C16H13D2Cl2N5OS2
- Masse moléculaire:430.37
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
EC50: 2.21 μM (Piezo1)
Piezo1 agonist 1-d2 (compound 12a) (0.125-32 μM; 2 h) potently activates Piezo1 and induces Ca2+ influx in C3H10T1/2 mesenchymal stem cells (MSCs), with an EC50 of 2.21 μM[1].
Piezo1 agonist 1-d2 (3-5 μM; 72 h) promotes osteogenesis of bone marrow mesenchymal stem cells (BMSCs) in a dose-dependent manner, and upregulates the expression of Runx2 and Osxm RNA[1].
Piezo1 agonist 1-d2 (5 μM; 5-15 min) activates the Erk signaling pathway in BMSCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:bone marrow mesenchymal stem cells (BMSCs)
-
Concentration:3, 5 μM
-
Incubation Time:72 h
-
Result:Significantly upregulated Runx2 mRNA levels at 3 μM, but did not significantly alter Osx mRNA levels.
Significantly upregulated both Runx2 mRNA levels and Osx mRNA levels at 5 μM.
-
Cell Line:bone marrow mesenchymal stem cells (BMSCs)
-
Concentration:5 μM
-
Incubation Time:5, 10, 15 min
-
Result:Significantly increased p-Erk levels at 5 min.
Showed higher p-Erk/Erk ratios at 5, 10, and 15 min compared to vehicle control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (2 months old, hindlimb-unloading osteoporosis model)[1]
-
Dosage:5 μM/kg
-
Administration:i.p.; 5 doses on days 1, 4, 7, 10, 13 after hindlimb unloading initiation
-
Result:Increased bone volume fraction (BV/TV), trabecular number (Tb.N.), and reduced trabecular separation (Tb.Sp.) compared to untreated hindlimb-unloading group.
Significantly increased Alp fluorescent area (osteogenic marker) relative to untreated hindlimb-unloading group, with osteogenesis levels nearly matching weight-bearing control rats.
Showed no significant liver or kidney toxic side effects during treatment.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 3058199-62-2
-
Masse moléculaire 430.37
-
Formule C16H13D2Cl2N5OS2
-
SMILES
ClC1=C(C(Cl)=CC=C1)C([2H])(SC2=NN=C(S2)C3=CN=C(C=N3)NC[C@@H](C)O)[2H]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Piezo1 agonist 1-d2 Related Classifications
HY-169332 Related Classifications
Powered by Bioz